Capricor Therap Cmn (CAPR) 3.63 $CAPR Capricor
Post# of 273242
Posted On: 09/23/2016 3:03:00 AM
Capricor Therap Cmn (CAPR) 3.63 $CAPR
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
PR Newswire - Wed Sep 21, 10:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the closing of its previously announced underwritten registered public offering and concurrent registered direct offering. In the registered public offering, a total of 3,090,625 shares of the Company's common stock were sold at an offering price of $3.20 per share. The shares include 403,125 shares of common stock sold pursuant to the underwriters' over-allotment option, which option was exercised in full. In the registered direct offering, a total of 312,500 shares of the Company's common stock were sold by Capricor directly to Cedars-Sinai Medical Center at a price of $3.20 per share.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Announces Pricing of Offerings of Common Stock
PR Newswire - Fri Sep 16, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the pricing of its offerings of 3,000,000 shares of its common stock at an offering price of $3.20 per share, before underwriting discounts. 2,687,500 shares of Capricor's common stock will be purchased by the underwriters in an underwritten registered public offering and 312,500 shares will be purchased by Cedars-Sinai Medical Center, a stockholder of Capricor, from Capricor directly and not through the underwriters in a concurrent registered direct offering. Capricor has granted the underwriters a 30-day option to purchase up to an additional 403,125 shares of its common stock. The proceeds to Capricor from the offerings are expected to be approximately $8.7 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. All shares of common stock to be sold in the offerings are being offered by Capricor. The offerings are expected to close on or about September 21, 2016, subject to customary closing conditions.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Sep 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc., are acting as joint book-running managers for the offering.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
PR Newswire - Wed Sep 07, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that the randomized Phase I/II HOPE-Duchenne clinical trial has completed its enrollment with 25 subjects. HOPE (Halt cardiomyOPathy progrEssion in Duchenne) is evaluating CAP-1002, Capricor's lead investigational cardiac cell therapy, in Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. Capricor expects to report top-line six-month data from this trial in the first quarter of 2017.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
PR Newswire - Thu Sep 01, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for cardiac and inflammatory conditions, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at BioCentury's 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 3:00 pm EDT in New York City.
CAPR: 3.63 (+0.06)
Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update
PR Newswire - Mon Aug 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided an update on its clinical development programs directed toward the treatment of heart disease, including that associated with Duchenne Muscular Dystrophy (DMD), as well as defined the initial development path for its proprietary exosomes technology. Capricor also announced financial results for the quarter ended June 30, 2016.
CAPR: 3.63 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 15, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held August 15, 2016 at 4:30 PM Eastern Time.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Monday, August 15 at 4:30 p.m. ET
PR Newswire - Fri Aug 12, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss second quarter 2016 financial results and recent business highlights at 4:30 p.m. ET on Monday, August 15, 2016.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.63 (+0.06)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.63 (+0.06)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.63 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.63 (+0.06)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.63 (+0.06), STAA: 9.50 (+0.06), AKER: 3.23 (-0.11), VBLT: 4.86 (+0.11)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.63 (+0.06)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.63 (+0.06), CSII: 23.66 (-0.34), BAX: 48.20 (+0.28), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 23.73 (unch), CAPR: 3.63 (+0.06), CSII: 23.66 (-0.34), ABAX: 52.84 (+0.99)
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
PR Newswire - Wed Sep 21, 10:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the closing of its previously announced underwritten registered public offering and concurrent registered direct offering. In the registered public offering, a total of 3,090,625 shares of the Company's common stock were sold at an offering price of $3.20 per share. The shares include 403,125 shares of common stock sold pursuant to the underwriters' over-allotment option, which option was exercised in full. In the registered direct offering, a total of 312,500 shares of the Company's common stock were sold by Capricor directly to Cedars-Sinai Medical Center at a price of $3.20 per share.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Announces Pricing of Offerings of Common Stock
PR Newswire - Fri Sep 16, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the pricing of its offerings of 3,000,000 shares of its common stock at an offering price of $3.20 per share, before underwriting discounts. 2,687,500 shares of Capricor's common stock will be purchased by the underwriters in an underwritten registered public offering and 312,500 shares will be purchased by Cedars-Sinai Medical Center, a stockholder of Capricor, from Capricor directly and not through the underwriters in a concurrent registered direct offering. Capricor has granted the underwriters a 30-day option to purchase up to an additional 403,125 shares of its common stock. The proceeds to Capricor from the offerings are expected to be approximately $8.7 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. All shares of common stock to be sold in the offerings are being offered by Capricor. The offerings are expected to close on or about September 21, 2016, subject to customary closing conditions.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Sep 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc., are acting as joint book-running managers for the offering.
CAPR: 3.63 (+0.06), NHLD: 3.22 (-0.08)
Capricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy
PR Newswire - Wed Sep 07, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that the randomized Phase I/II HOPE-Duchenne clinical trial has completed its enrollment with 25 subjects. HOPE (Halt cardiomyOPathy progrEssion in Duchenne) is evaluating CAP-1002, Capricor's lead investigational cardiac cell therapy, in Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. Capricor expects to report top-line six-month data from this trial in the first quarter of 2017.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
PR Newswire - Thu Sep 01, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies for cardiac and inflammatory conditions, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at BioCentury's 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 3:00 pm EDT in New York City.
CAPR: 3.63 (+0.06)
Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update
PR Newswire - Mon Aug 15, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided an update on its clinical development programs directed toward the treatment of heart disease, including that associated with Duchenne Muscular Dystrophy (DMD), as well as defined the initial development path for its proprietary exosomes technology. Capricor also announced financial results for the quarter ended June 30, 2016.
CAPR: 3.63 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016
ACCESSWIRE - Mon Aug 15, 8:02AM CDT
LOS ANGELES, CA / ACCESSWIRE / August 15, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held August 15, 2016 at 4:30 PM Eastern Time.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Monday, August 15 at 4:30 p.m. ET
PR Newswire - Fri Aug 12, 8:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss second quarter 2016 financial results and recent business highlights at 4:30 p.m. ET on Monday, August 15, 2016.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.63 (+0.06)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.63 (+0.06)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.63 (+0.06)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.63 (+0.06)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.63 (+0.06)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.63 (+0.06), STAA: 9.50 (+0.06), AKER: 3.23 (-0.11), VBLT: 4.86 (+0.11)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.63 (+0.06)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.63 (+0.06), CSII: 23.66 (-0.34), BAX: 48.20 (+0.28), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 23.73 (unch), CAPR: 3.63 (+0.06), CSII: 23.66 (-0.34), ABAX: 52.84 (+0.99)
(0)
(0)Scroll down for more posts ▼